Friedreich Ataxia
70
15
20
42
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.4%
1 terminated out of 70 trials
97.7%
+11.2% vs benchmark
6%
4 trials in Phase 3/4
24%
10 of 42 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 42 completed trials
Clinical Trials (70)
Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Clinical Course Of Disease In Participants With FA-CM
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Friedreich Ataxia Nerve Ultrasund
Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
Measurement of Frataxin mRNA in Biofluids
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
FRDA Investigator Initiated Study (IIS) With Elamipretide
A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia
Respiratory Training in Friedreich's Ataxia
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia